UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________
FORM 8-K
________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
| |
Date of Report (Date of Earliest Event Reported): May 29, 2020 (May 26, 2020) |
CUMBERLAND PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter) |
| | | |
| |
| Tennessee | 001-33637 | 62-1765329 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
| | | |
| 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203 |
| (Address of principal executive offices) (Zip Code) |
| | |
| (615) 255-0068 |
| (Registrant’s telephone number, including area code) |
| | | |
| Not Applicable |
| (Former name or former address, if changed since last report) |
____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| | |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
| | | | |
Class | | Trading Symbol | | Name of exchanged on which registered |
Common stock, no par value | | CPIX | | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events
On May 26, 2020, Cumberland announced a new publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.
The Telavancin Observational Use Registry (TOUR™) was conducted to record population characteristics, prescription information, and real-world clinical outcomes of patients with Gram-positive infections treated with Vibativ. This publication assessed 151 patients in TOUR™ with endocarditis and/or bacteremia with a known or unknown primary source.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | | | |
| | | | Cumberland Pharmaceuticals Inc. |
| | | |
Dated: May 29, 2020 | | | | By: | /s/ Michael Bonner |
| | | | | Michael Bonner |
| | | | | Chief Financial Officer |
| | | | | | |
Item 9.01. Financial Statements and Exhibits.
|
| | |
| | |
Exhibit No. | | Description |
| | |
99.1 | | |
| | |